Skip to main content
. 2023 Jun 29;24:269. doi: 10.1186/s12859-023-05399-6

Fig. 1.

Fig. 1

SLC25A17 expression and clinical prognosis of HNSCC based on TIMER2.0 and TCGA databases. A Expression of SLC25A17 in different tumors and normal para-carcinoma tissues; B expression of SLC25A17 in HNSCC tumors and normal tissues in all included patients; C expression of SLC25A17 in HNSCC tumors and normal para-carcinoma tissues in the same individual; D IHC slides show that expression of SLC25A17 in HNSCC tissues was higher than that in normal tissues; E overall survival K‒M survival curve; F progression-free survival K‒M survival curve. (**P < 0.01; ***P < 0.001)